References: 1. Sensipar® (cinacalcet) prescribing information, Amgen. 2. Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. Med Clin N Am. 2005;89:631-647. 3. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148-157. 4. Wesseling-Perry K, Harkins GC, Wang H, et al. The calcemic response to continuous parathyroid hormone (PTH) (1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH (7-84). J Clin Endocrinol Metab. 2010;95:2772-2780. 5. Komaba H, Shiizaki K, Fukagawa M. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges. Expert Opin Biol Ther. 2010;10:1729-1742. 6. Goodman WG, Quarles LD. Vitamin D, calcimimetics, and phosphate-binders: phosphate binding agents. In: Brenner BM, Levine SA, eds. Brenner & Rector’s The Kidney. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1919-1921. 7. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446-456. 8. Data on file, Amgen; [ESRD Dialysis Patient Chart Audit; Q2 2014]. 9. Data on file, Amgen; [Cinacalcet Integrated Analyses of Efficacy; 2003]. 10. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36-45. 11. Ureña-Torres P, Bridges I, Christiano C, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28:1241-1254. 12. Data on file, Amgen; [Clinical Study Report 20070360–Incident Dialysis Study; June 27, 2012]. 13. Data on file, Amgen; [Pooled phase 3 PTH and calcium reductions by baseline calcium analysis; November 2012]. 14. Food and Drug Administration Center for Drug Evaluation and Research. Clinical review for NDA 21-688 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm. Accessed June 21, 2015. 15. Brunelli SM, Dluzniewski P, Cooper K, Do T, Sibbel S, Bradbury BD. Serum calcium reductions among patients on hemodialysis initiating cinacalcet. Poster presented at: The American Society of Nephrology Renal Week; November 11-16, 2014; Philadelphia, PA. 16. Data on file, Amgen; [Pooled phase 3 concurrent achievement of PTH and serum phosphorus targets during the efficacy assessment phase; November 2014]. 17. Data on file, Amgen; [Cinacalcet New to Brand Patient Persistency; 2008-2014]. 18. Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2016 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. April 2015. Available at: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Announcements-and-Documents-Items/2016Announcement.html. Accessed January 12, 2016. 19. Centers for Medicare & Medicaid Services. Medicare Program; End–Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule. Fed Regist. 2014;79:66210-66265. Codified at 42 CFR Parts 405, 411, 413, and 414.